Search bioRxivSearch

bioRxiv · 10.1101/463059

Serological proteomic screening and evaluation of a recombinant egg antigen for the diagnosis of low-intensity infections in endemic area in Brazil

Abstract

BackgroundDespite decades of employment of control programs, schistosomiasis remains a global public health problem. To further reduce prevalence and intensity of infection, or to achieve the goal of elimination in low-endemic areas, there need to be better diagnostic tools to detect low intensity infections in low-endemic areas as Brazil. The rationale for development of new diagnostic tools is because in low-endemic settings, the standard Kato-Katz diagnostic method loses its sensitivity and misses low intensity infections. To develop new diagnostic tools, we employed a proteomics approach search for biomarkers associated with schistosome-specific immune responses to develop sensitive and specific new methods for immunodiagnosis.\n\nMethods and findingsImmunoproteomic analysis was performed on an egg extract of Schistosoma mansoni using pooled sera from infected or non-infected individuals from a low-endemic area of Brazil. Cross reactivity with other helminth parasites was determined using pooled sera from individuals infected with different parasitic helminths. Using this approach we identified 23 spots recognized by schistosome acute and chronic sera samples. To identify immunoreactive spots that are likely glycan epitopes, we compared immunoreactivity of spots treated by sodium metaperiodate oxidation of egg extract. This treatment yielded 12/23 spots maintaining immunoreactivity, suggesting they are protein epitopes. From these 12 spots, 11 spots cross-reacted with sera from infection with other helminths and 10 spots cross-reacted with the negative control group. Spot number 5 was exclusively immunoreactive with sera from schistosome-infected groups in native and deglycosylated conditions and corresponds to a Major Egg Antigen. We expressed the Major egg antigen as a recombinant protein and showed by western blot a similar recognition pattern of that of the native protein. IgG-ELISA gave a sensitivity of 87.10% and specificity of 89.09% represented by area under ROC curve of 0.95. IgG-ELISA performed better than the conventional K-K (2 slides) identifying 56/64 cases harboring 1-10 egg per gram of feces that were undiagnosed by K-K parasitological technique.\n\nConclusionsThe serological proteome approach was able to identify a new diagnostic candidate. The recombinant egg antigen provided good performance in IgG-ELISA to detect individuals with extreme low-intensity infections (1 egg per gram of feces). Therefore, the IgG-ELISA using this newly identified recombinant major egg antigen can be a useful tool to be combined with other techniques in low-endemic areas to determine the true prevalence of schistosome infection that is underestimated by Kato-Katz method. Further, to overcome the complexity of ELISA in the field, a second-generation of antibody-based rapid diagnostic tests (RDT) can be developed.\n\nAuthor SummarySchistosomiasis remains a serious global public health problem. Detecting parasite eggs in patient stool samples using the Kato-Katz (KK) method is the standard diagnostic recommended by World Health Organization (WHO) for infection by Schistosoma mansoni. As a result of intensive control strategies, many previously high-endemic areas are now considered low-endemic areas and the K-K method does not function well in low-endemic areas and therefore cannot be considered the gold standard. Thus, a new emphasis on strategies to accurately diagnose low-intensity infections was outlined in plan from WHO focusing on elimination of disease as a public health problem. Successful diagnoses and treatment of the majority of infected individuals may result in elimination of a sufficient number of low-burden transmitters and consequently, in the interruption of the disease transmission. In this regard, immunological techniques have proven to be more sensitive and promising for identifying infection in low-intensity of infection positive individuals with negative K-K results. The identification of antigens is the initial step for developing new immunodiagnostic assays. In this study, we used sets of pooled human sera samples from controls to acute and chronic infections to narrow down the number of new candidate antigens via proteomic screening. Using these approaches we initially identified 12 different egg proteins in schistosome-infected individuals (acute and chronic phase). A single antigen identified as Major Egg Antigen was shown to be highly specific as this antigen was not recognized by sera from negative or patients infected with other helminths. The recombinant Major Egg Antigen protein functioned in ELISA as a highly sensitive and specific antigen to detect patient IgG-antibodies. Recombinant Major Egg Antigen performed significantly better to detect low-intensity infections (1 egg per gram of feces) than the K-K method using 2 slides. Therefore, using a proteomic screening approach we were able to identify a potential new candidate antigen for development of far more sensitive diagnostic assays. Further diagnostic assays employing the Major Egg Antigen could be a useful tool on its own or in combination with other methods for diagnosis of schistosome infection in populations living in extreme low-intensity endemic areas of Brazil.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Moraes, V., Shollenberger, L. M., Castro-Borges, W., Rabello, A. L. T., Harn, D. A., Medeiros, L. C. S., Jeremias, W. d. J., Siqueira, L. M. V., Pereira, C. S. S., Pedrosa, M. L. C., Almeida, N. B. F., Almeida, A., Lambertucci, J. R., Carneiro, N. F. F., Coelho, P. M. Z., Grenfell, R. F. Q.. 2018-11-05. Serological proteomic screening and evaluation of a recombinant egg antigen for the diagnosis of low-intensity infections in endemic area in Brazil. https://doi.org/10.1101/463059

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

De novo design of CR2 binder as vaccine scaffold

Efficient B cell activation during vaccine-induced humoral immunity relies on both B cell receptor (BCR) antigen recognition and synergistic signaling from co-receptors. Complement receptor 2 (CR2), the primary BCR co-receptor on B cells, lowers the activation threshold and amplifies downstream kinase signaling by orders of magnitude when engaged by complement fragment C3d decorated antigens. Targeting CR2 therefore represents a rational vaccine enhancement strategy, yet native C3d suffers from low affinity, poor stability, and manufacturing challenges. Here, we report the de novo design of a highly stable, high-affinity CR2 binder using deep learning driving protein design methods. Biophysical characterization, high-resolution cryoEM structural determination, and functional assays in vitro and in vivo confirm that the designed binder matches computational design models and specifically engages CR2 to boost B cell activation. When fused to antigen as a vaccine scaffold, the trimeric CR2 binder elicits robust humoral immune responses comparable to nanoparticle vaccines, while retaining the simplicity of single-chain protein production. Our work establishes a modular CR2 targeting vaccine scaffold platform with broad translational potential for next-generation protein vaccines.

immunology

Chronic opioid-associated immune dysregulation among people living with HIV

Objectives: Persistent immune dysregulation contributes to chronic disease among people living with HIV (PWH), even after viral suppression with antiretroviral therapy (ART). Although chronic opioid exposure is associated with adverse clinical outcomes, its impact on immune homeostasis during ART remains incompletely understood. We investigated whether opioid use disorder (OUD) is associated with persistent systemic and cellular immune dysregulation despite ART-mediated reductions in HIV viral load (VL). Methods: Peripheral blood was collected longitudinally from PWH with OUD (PWH/OUD+) and detectable HIV VL during 6 months of optimized ART (months 0, 3, and 6). A reference cohort of PWH without OUD (PWH/OUD-) and suppressed HIV VL provided a single blood sample. Immune profiling included plasma inflammatory biomarkers, multiplex cytokine analyses, spectral flow cytometry, and assessment of monocyte cytokine responses following lipopolysaccharide (LPS) stimulation. Mixed-effects models adjusted for HIV VL and VL-stratified analyses were performed. Results: PWH/OUD+ exhibited persistent immune dysregulation despite reductions in HIV VL. Plasma sCD163, sCD14, fractalkine, and I-TAC remained elevated, whereas TGF-{beta}1 was reduced. OUD was associated with expansion of CD16 monocytes and altered expression of CCR2, CD38, and CD11b. CD4 and CD8 T cells, NK cells, and B cells also exhibited persistent alterations in markers of activation, metabolism, and trafficking. Monocytes from PWH/OUD+ displayed attenuated cytokine responses following LPS stimulation. Conclusions: OUD is associated with persistent systemic and cellular immune dysfunction in PWH despite ART-mediated viral suppression, supporting opioid exposure as an independent contributor to chronic immune dysregulation that may promote inflammation, immune dysfunction, and long-term HIV-associated comorbidities. Keywords: HIV, Opioid-use disorder, innate immunity, cytokine

immunology

The mitochondrial RNA extrusion-induced innate immunity is regulated by N6-methyladenosine machinery

Mitochondrial RNA (mtRNA) released into the cytosol functions as a damage associated molecular pattern that activates pattern-recognition receptor (PRR)-mediated inflammation, yet its release mechanisms and cytoplasmic fate remain poorly understood. Here we report that chemical Abt-373-treatment and Vesicular stomatitis virus (VSV) infection induce mtRNA extrusion through Bax/Bak and VDAC1 channels, accompanied by mtDNA release. Extruded mtRNA in A549 cells activates multiple cytosolic PRRs, including RIG-I, MDA5, TLR3/7/8, and PKR, each contributing differentially to the innate immune signaling. Analysis of GEO datasets and methylated RNA immunoprecipitation (MeRIP) assays further reveals that mtRNA carries methyladenosine (m6A) modification. m6A machinery proteins are involved in the cytoplasmic retention time of mtRNA and its interaction with RIG-I, thereby modulating mtRNA-induced innate immunity. Thus, our work establishes in vitro models of mtRNA extrusion, and highlights m6A-dependent modulation as a potential therapeutic target for mtRNA-driven inflammation.

immunology